Next-gen assays for better cancer diagnosis
July 2017
SHARING OPTIONS:

IRVINE, Calif. & HERSTAL, Belgium—A new agreement is underway between MDxHealth SA and the faculty of Health, Medicine and Life Sciences/School for Oncology and Developmental Biology (GROW) at Maastricht University that expands an existing research collaboration. The agreement focuses on the development of next-generation epigenetic-based assays for the diagnosis, staging and treatment of cancer patients. The assays will be centered on sample-in and result-out-based platforms, and the technology would also be applied to MDxHealth’s liquid biopsy tests.
 
“GROW at Maastricht University are true visionaries and we are fortunate to have such a longstanding and collaborative relationship,” said Dr. Jan Groen, CEO of MDxHealth. “The development of next-generation liquid biopsy diagnostics for oncology will be game-changing and help physicians manage their patients faster and more effectively.”

Back
 
CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.